Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study

Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study

Abstract Introduction Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Biologic drugs have a key role in the long-term anti-inflammatory treatment of moderate to severe patients due to their immunomodulatory properties. The aim of this study is to evaluate the effectiveness and...

Full description

Bibliographic Details
Main Authors: Pablo Fernandez-Crehuet, Sofía Haselgruber, Alicia Padial-Gomez, Fiorella Vasquez-Chinchay, Maria Dolores Fernandez-Ballesteros, Irene López-Riquelme, David Jimenez-Gallo, Juan Manuel Segura-Palacios, Marisol Contreras-Steyls, Giovana Fernanda Osorio-Gómez, Juan Carlos Hernández-Rodríguez, Manuel Sanchez-Diaz, Carlos Cuenca-Barrales, Salvador Arias-Santiago, Alejandro Molina-Leyva
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-03-01
Series:Dermatology and Therapy
Subjects:
Hidradenitis suppurativa
Secukinumab
Anti-IL-17
Hidradenitis suppurativa clinical response
HiSCR
Therapeutic burden
Online Access:https://doi.org/10.1007/s13555-023-00906-2

Internet

https://doi.org/10.1007/s13555-023-00906-2

Similar Items